Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)
Trial Parameters
Brief Summary
RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.
Eligibility Criteria
Inclusion Criteria: * Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention). * patients who already took or plan to take rivoxban * patients who able to use smart phone Exclusion Criteria: * creatinine clearance \<15ml/min * moderate or severe mitral stenosis * mitral valve operation history * current alcohol abuse or alcohol abus history * Not eligible for study due to legal or psychiatric problem * enrolled other clinical study within 4 weeks * declined to enroll the study